BioSpace News Archive

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that three abstracts highlighting PyLTM (18F-DCFPyL), I-131 1095, and PSMA AI have been selected for oral and poster presentations at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2019 and reviewed recent business highlights.

Arch Biopartners Inc.,, announced it has closed the non-brokered, unsecured convertible note financing it disclosed in a press release on February 4th for net proceeds of CAD $500,000.

FDA grants Type C meeting for SB206 to be held on April 1, 2020 Last subject completes last visit, Week 24 safety evaluation Additional 12-week efficacy and safety data provided MORRISVILLE, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today provided an update on several aspects of its Phase 3 B-SIMPLE program (B-SIMPLE1 and B-SIMPLE2). Novan has been granted a Type C meeting with the U.S. Food and Drug Administration (“FDA”) on Apri

Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the upcoming presentation of three abstracts at the 16th Annual WORLDSymposium™, taking place February 10-13, 2020, in Orlando, FL.

Sonendo®, Inc., a dental technology company developing and commercializing products to save teeth through Sound Science®, announced the appointment of Andrew Kirkpatrick as Chief Operating Officer.

Feb. 6, 2020 13:30 UTC Fusion Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D., to Board of Directors BOSTON & HAMILTON, Ontario--( BUSINESS WIRE )-- Fusion Pharmaceuticals Inc. , a clinical-stage precision oncology company developing targeted alpha therapeutics, today announced the appointment of Pablo J. Cagnoni, M.D., to the board of directors. Dr. Cagnoni’s appointment as an independent director adds an oncology drug development leader

Feb. 6, 2020 13:30 UTC IRVINE, Calif.--( BUSINESS WIRE )-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2019 is expected to be approximately $35.8 million. Revenue for the full year ended December 31, 2019 is expected to be approximately $143.4 million.

Memory Health LLC announced today that the United Kingdom Patent Office has issued a patent, related to the company’s uniquely-formulated Memory Health brain health supplement, for “the prevention and/or treatment of neurodegenerative disease.” “This is a major milestone in the endless quest to prevent and treat neurodegene

Survival outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) have made significant gains in recent years, but new research in the February 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds some groups are being left behind.